Brazil Approves First Generic Version Of Sovaldi
Brazil’s first generic version of Sovaldi for hepatitis C is approved.
You may also be interested in...
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Mercosur bloc has been conducting joint negotiations on HCV drugs; cancer treatments may be next on the agenda.
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.